Author/Authors :
Charehdar, S Department of Medical Parasitology and Mycology - School of Public Health and Institute of Public Health Research - Medical Sciences/University of Tehran - Tehran, Iran , Esmaeili, J Department of Medical Parasitology and Mycology - School of Public Health and Institute of Public Health Research - Medical Sciences/University of Tehran - Tehran, Iran , Mohebali, M Department of Medical Parasitology and Mycology - School of Public Health and Institute of Public Health Research - Medical Sciences/University of Tehran - Tehran, Iran , Edrissian, G. H. Department of Medical Parasitology and Mycology - School of Public Health and Institute of Public Health Research - Medical Sciences/University of Tehran - Tehran, Iran , Rezayat, S. M. Department of Pharmacology - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran , Ghazi-Khansari, M Department of Pharmacology - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran
Abstract :
Cutaneous leishmaniasis is endemic in 88 different countries. There are an estimated 1.5
million new cases each year, with over 90% occurring in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia,
Syria (Old World) and in Brazil and Peru (New World). Miltefosine is effective in vitro and in vivo
against Leishmania species and it was demonstrated efficacy in animals via the oral route. This study is
the first one for evaluating the effect of miltefosine on cutaneous leishmaniasis of L. major
(MRHO/IR/75/ER) by in vivo and in vitro studies in the BALB/c mouse model. As it was shown,
miltefosine has a better effect on reduction of size of lesion compared to Glucantime®, also it was not
significant by statistical analysis. The results of this study show that miltefosine has a good activity
against the proliferation of amastigotes of L. major. The results suggest that oral miltefosine might be a
promising approach for developing new anti-Leishmanial drugs.
Keywords :
treatment , Leishmania major , miltefosine , Cutaneous leishmaniasis
